When human peripheral blood mononuclear cells are engrafted into ultra-immunodeficient models, severe acute graft versus host disease (GvHD) is triggered, leaving a very limited window for experiments.
Researchers have long sought to extend these models' lifespan, and recently engineered a new strain, the B-NDG B2m, which combines the immunodeficient B-NDG mouse with the absence of MHC class I expression and retention of FcRn function.
This model shows prolonged antibody half-life as compared to B2m KO mice, as well as extended survival and delayed onset and severity of GvHD, compared to other models. Our white paper assesses the phenotypic, pharmacokinetic, and efficacy assessments for this double-knockout mouse strain.
For more insights, read our white paper, "Development, Characterization, and Validation of B-NDG B2m Double Knockout Plus Mice." Complete the form to receive your copy today.
